The role of pelvic lymphadenectomy for prostate cancer-therapeutic?

Journal of Urology

Volumn 179, Issue 2, 2008, Pages 408-413

  Wagner, M ^a   Sokoloff, M ^a   Daneshmand, S ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Lymph node excision; Neoplasm staging; Prostate; Prostatic neoplasms; Risk

Indexed keywords

CHOLINE C 11; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE;

CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER SURVIVAL; CLINICAL TRIAL; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; DEEP VEIN THROMBOSIS; DISEASE SEVERITY; HISTOPATHOLOGY; HUMAN; LEG EDEMA; LYMPH NODE; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; LYMPHADENECTOMY; LYMPHEDEMA; LYMPHOCELE; MICROMETASTASIS; MORBIDITY; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PELVIS LYMPHADENECTOMY; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE COMPLICATION; PREOPERATIVE EVALUATION; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; PROSTATE CANCER; PROSTATECTOMY; REVIEW; RISK FACTOR; SURGICAL TECHNIQUE; CANCER STAGING; MALE; MORTALITY; PATHOLOGY; PELVIS; PROSTATE TUMOR; SURVIVAL RATE;

HUMANS; LYMPH NODE EXCISION; MALE; NEOPLASM STAGING; PELVIS; PROSTATIC NEOPLASMS; SURVIVAL RATE;

EID: 38849146575     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2007.09.027     Document Type: Review

References (38)

1. Cunéo B and Marcille M: Note sur les lymphatiques de la vessie. Bull Mem Soc Anat 1901;6:649.
2. Janoff DM and Parra RO: Contemporary appraisal of radical perineal prostatectomy. J Urol 2005;173:1863.
3. Freiha FS and Salzman J: Surgical staging of prostatic cancer: transperitoneal versus extraperitoneal lymphadenectomy. J Urol 1977;118:616.
4. Castellino RA, Ray G, Blank N, Govan D and Bagshaw M: Lymphangiography in prostatic carcinoma. Preliminary observations. JAMA 1973;223:877.
5. Raghavaiah NV and Jordan WP Jr: Prostatic lymphography. J Urol 1979;121:178.
6. Fowler JE Jr and Whitmore WF Jr: The incidence and extent of pelvic lymph node metastases in apparently localized prostatic cancer. Cancer 1981;47:2941.
7. McDowell GC 2nd, Johnson JW, Tenney DM and Johnson DE: Pelvic lymphadenectomy for staging clinically localized prostate cancer. Indications, complications, and results in 217 cases. Urology 1990;35:476.
8. Schwartz KL, Severson RK, Gurney JG and Montie JE: Trends in the stage specific incidence of prostate carcinoma in the Detroit metropolitan area, 1973-1994. Cancer 1996;78:1260.
9. Allaf ME, Palapattu GS, Trock BJ, Carter HB and Walsh PC: Anatomical extent of lymph node dissection: impact on men with clinically localized prostate cancer. J Urol 2004;172:1840.
10. Roehl KA, Han M, Ramos CG, Antenor JA and Catalona WJ: Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3, 478 consecutive patients: long-term results. J Urol 2004;172:910.
11. Palapattu GS, Allaf ME, Trock BJ, Epstein JI and Walsh PC: Prostate specific antigen progression in men with lymph node metastases following radical prostatectomy: results of long-term followup. J Urol 2004;172:1860.
12. Gervasi LA, Mata J, Easley JD, Wilbanks JH, Seale-Hawkins C, Carlton CE Jr et al: Prognostic significance of lymph nodal metastases in prostate cancer. J Urol 1989;142:332.
13. Messing EM, Manola J, Yao J, Kiernan M, Crawford D, Wilding G et al: Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 2006;7:472.
14. Clark T, Parekh DJ, Cookson MS, Chang SS, Smith ER Jr, Wells N et al: Randomized prospective evaluation of extended versus limited lymph node dissection in patients with clinically localized prostate cancer. J Urol 2003;169:145.
15. Briganti A, Chun FK, Salonia A, Suardi N, Gallina A, Da Pozzo LF et al: Complications and other surgical outcomes associated with extended pelvic lymphadenectomy in men with localized prostate cancer. Eur Urol 2006;50:1006.
16. Heidenreich A, Varga Z and Von Knobloch R: Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis. J Urol 2002;167:1681.
17. Bigg SW and Catalona WJ: Prophylactic mini-dose heparin in patients undergoing radical retropubic prostatectomy. A prospective trial. Urology 1992;39:309.
18. Soh S, Kattan MW, Berkman S, Wheeler TM and Scardino PT: Has there been a recent shift in the pathological features and prognosis of patients treated with radical prostatectomy? J Urol 1997;157:2212.
19. Bader P, Burkhard FC, Markwalder R and Studer UE: Is a limited lymph node dissection an adequate staging procedure for prostate cancer? J Urol 2002;168:514.
20. Wang L, Hricak H, Kattan MW, Schwartz LH, Eberhardt SC, Chen HN et al: Combined endorectal and phased-array MRI in the prediction of pelvic lymph node metastasis in prostate cancer. AJR Am J Roentgenol 2006;186:743.
21. de Jong IJ, Pruim J, Elsinga PH, Vaalburg W and Mensink HJ: Preoperative staging of pelvic lymph nodes in prostate cancer by 11C-choline PET. J Nucl Med 2003;44:331.
22. Partin AW, Kattan MW, Subong EN, Walsh PC, Wojno KJ, Oesterling JE et al: Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 1997;277:1445.
23. Blute ML, Bergstralh EJ, Partin AW, Walsh PC, Kattan MW, Scardino PT et al: Validation of Partin tables for predicting pathological stage of clinically localized prostate cancer. J Urol 2000;164:1591.
24. Bishoff JT, Reyes A, Thompson IM, Harris MJ, St Clair SR, Gomella L et al: Pelvic lymphadenectomy can be omitted in selected patients with carcinoma of the prostate: development of a system of patient selection. Urology 1995;45:270.
25. Meng MV and Carroll PR: When is pelvic lymph node dissection necessary before radical prostatectomy? A decision analysis. J Urol 2000;164:1235.
26. Kawakami J, Meng MV, Sadetsky N, Latini DM, Duchane J, Carroll PR et al: Changing patterns of pelvic lymphadenectomy for prostate cancer: results from CaPSURE. J Urol 2006;176:1382.
27. Masterson TA, Bianco FJ Jr, Vickers AJ, DiBlasio CJ, Fearn PA, Rabbani F et al: The association between total and positive lymph node counts, and disease progression in clinically localized prostate cancer. J Urol 2006;175:1320.
28. Briganti A, Chun FK, Salonia A, Gallina A, Farina E, Da Pozzo LF et al: Validation of a nomogram predicting the probability of lymph node invasion based on the extent of pelvic lymphadenectomy in patients with clinically localized prostate cancer. BJU Int 2006;98:788.
29. Chun KF, Roman H, Heinzer H, Graefen M, Huland H, Briganti A et al: Number of lymph nodes removed and examined and the continent of origin represent the foremost predictors of lymph node invasion in men with clinically localized prostate cancer. J Urol, suppl., 2007: 175: 310, abstract 963.
30. Weckermann D, Dorn R, Trefz M, Wagner T, Wawroschek F and Harzmann R: Sentinel lymph node dissection for prostate cancer: experience with more than 1,000 patients. J Urol 2007;177:916.
31. Studer UE: Editorial comment. J Urol 2003;169:148.
32. Bader P, Burkhard FC, Markwalder R and Studer UE: Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure? J Urol 2003;169:849.
33. Daneshmand S, Quek ML, Stein JP, Lieskovsky G, Cai J, Pinski J et al: Prognosis of patients with lymph node positive prostate cancer following radical prostatectomy: longterm results. J Urol 2004;172:2252.
34. Joslyn SA and Konety BR: Impact of extent of lymphadenectomy on survival after radical prostatectomy for prostate cancer. Urology 2006;68:121.
35. Pagliarulo V, Hawes D, Brands FH, Groshen S, Cai J, Stein JP et al: Detection of occult lymph node metastases in locally advanced node-negative prostate cancer. J Clin Oncol 2006;24:2735.
36. Bhatta-Dhar N, Reuther AM, Zippe C and Klein EA: No difference in six-year biochemical failure rates with or without pelvic lymph node dissection during radical prostatectomy in low-risk patients with localized prostate cancer. Urology 2004;63:528.
37. DiMarco DS, Zincke H, Sebo TJ, Slezak J, Bergstralh EJ and Blute ML: The extent of lymphadenectomy for pTXNO prostate cancer does not affect prostate cancer outcome in the prostate specific antigen era. J Urol 2005;173:1121.
38. Ghavamian R, Bergstralh EJ, Blute ML, Slezak J and Zincke H: Radical retropubic prostatectomy plus orchiectomy versus orchiectomy alone for pTxN+ prostate cancer: a matched comparison. J Urol 1999;161:1223.